Anthony Mancini, serving as the Chief Global Commercialization Officer at Revolution Medicines, Inc. (NASDAQ:RVMD), completed the sale of 4,615 shares of common stock on June 16, 2026. The transaction resulted in proceeds totaling approximately $720,490. The shares were disposed of at prices ranging between $156.1105 and $156.8250 per share, with a calculated weighted average price of $156.1192. This transaction was classified as an automatic "sell-to-cover" event, executed solely to satisfy applicable withholding tax obligations following the vesting of restricted stock units.
Following the transaction, Mancini's direct holdings in Revolution Medicines common stock stand at 49,975 shares. This total encompasses 43,700 Restricted Stock Units and 190 shares acquired through the company's Employee Stock Purchase Plan on May 31, 2026.
The timing of this sale coincides with Revolution Medicines trading near its 52-week high of $166.50, with shares currently valued at $162.99. According to InvestingPro data, the stock has generated a 295% return over the past year. However, InvestingPro analysis indicates the stock appears overvalued relative to its Fair Value estimate, placing it among companies on the most overvalued list.
Recent analyst updates following new clinical trial data have focused on Revolution Medicines. The company's RASolute 302 trial demonstrated significant results, achieving overall survival of 13.2 months and progression-free survival of 7.3 months in the G12X subgroup. Stifel reiterated a Buy rating and set a price target of $215, highlighting the trial's positive outcomes. TD Cowen also maintained a Buy rating, emphasizing the trial's success in meeting its primary endpoints. RBC Capital raised its price target to $182, citing Revolution's competitive edge in the RAS oncology space and maintaining an Outperform rating. UBS reiterated a Buy rating with a price target of $175, following promising data from a combination trial involving Revolution's drug daraxonrasib. RBC Capital further reinforced its positive outlook, expecting Revolution's drug to become a leader in the pancreatic ductal adenocarcinoma market.